Abstract
Background
Methotrexate (MTX), an antimetabolite of folic acid, is the drug of choice for the nonsurgical management of ectopic pregnancy. MTX-related toxicity may include leukopenia, thrombocytopenia, pancytopenia, nausea, vomiting, stomatitis, mucositis, and liver and lung toxicity, depending primarily on the dosage of the drug and patients' renal function. Currently, the use of MTX in hemodialysis patients, even at a low dosage, is controversial, and no clear-cut guidelines are available.
Case report
We report here a rare case of a life-threatening complication characterized by severe pancytopenia and skin and mucosal injury, which developed in a young patient on hemodialysis after oral treatment with MTX for ectopic pregnancy.
Conclusion
We conclude that even low-dose MTX administration is not to be used in patients with renal insufficiency, and when no other therapeutic options are available we suggest taking several clinical measures to prevent or treat myelosuppression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Huffman DH, Wan SH, Azarnoff DL et al (1973) Pharmacokinetics of methotrexate. Clin Pharmacol Ther 14:572–579
Yang CP, Kuo MC, Guh JY, Chen HC (2006) Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature. Ren Fail 28(1):95–97
Nakamura M, Sakemi T, Nagasawa K (1999) Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol 26:1424–1425
Boulanger H, Launay-Vacher V, Hierniaux P, Fau JB, Deray G (2001) Severe methotrexate intoxication in a hemodialysis patient treated for rheumatoid arthritis. Nephrol Dial Transplant 16:1087
Cheung K, Chow KM, Szeto CC, Tai MH, Kwan BC, Li PK (2009) Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. J Clin Rheumatol 15(4):177–180
Kelly H, Harvey D, Moll S (2006) A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol 107(2):439–441
Calabresi P, Chabner BA (1990) Antineoplastic agents, chapter 52. In: Gilman A, Goodman LS, Goodman A (eds) The pharmacological basis of therapeutics, 8th edn. Macmillan, New York, pp 1275–1276
Frei E 3rd, Blum RH, Pitman SW et al (1980) High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity. Am J Med 3:370–376
Thomson AH, Daly M, Knepil J, Harden P, Symonds P (1996) Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. Cancer Chemother Pharmacol 38:566–570
Ferreri AJ, Reni M, Pasini F et al (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58(10):1513–1520
Ellman MH, Ginsberg D (1990) Low-dose methotrexate and severe neutropenia in patients undergoing renal dialysis. Arthritis Rheum 33:1060–1061
Basile C, Montanaro A, Semeraro A (2002) Should low dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transplant 17:530–531
Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21(1):33–64
Saland JM, Leavey PJ, Bash RO et al (2002) Effective removal of methotrexate by highflux hemodialysis. Pediatr Nephrol 17:825–829
Conflicts of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Willner, N., Storch, S., Tadmor, T. et al. Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy. Eur J Clin Pharmacol 70, 261–263 (2014). https://doi.org/10.1007/s00228-013-1608-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-013-1608-3